Swine Vaccines MarketSize, Share & Industry Analysis, 2026-2034By Vaccine TypeBy Target DiseaseBy ValencyBy Route of AdministrationBy Production Stage/animal ClassBy Distribution ChannelBy End User/farm TypeBy Technology PlatformBy Dose Format/packagingBy Vaccination Program Type
Full title & scope — all 10 axes with their segments
Swine Vaccines Market Size, Share & Industry Analysis, By Vaccine Type (Inactivated (Killed) Vaccines, Live Attenuated Vaccines, Recombinant/Subunit Vaccines, DNA/Nucleic Acid Vaccines, Toxoid Vaccines), By Target Disease (Porcine Reproductive and Respiratory Syndrome, Porcine Circovirus Type 2, Classical Swine Fever, African Swine Fever, Swine Influenza, Mycoplasma Hyopneumoniae, Actinobacillus Pleuropneumoniae, Porcine Epidemic Diarrhea Virus (PEDV) & Enteric Diseases, Pseudorabies, Porcine Parvovirus & Erysipelas), By Valency (Monovalent Vaccines, Bivalent Vaccines, Multivalent/Combination Vaccines), By Route of Administration (Intramuscular Injection, Subcutaneous Injection, Intranasal Administration, Oral Administration), By Production Stage/animal Class (Sows & Gilts, Boars, Suckling Piglets, Weaners, Growers & Finishers), By Distribution Channel (Veterinary Hospitals & Clinics, Retail Pharmacies/Agrovet Stores, Direct/Institutional Sales to Integrators, e-Commerce/Online Platforms), By End User/farm Type (Commercial/Industrial Farms, Integrated Pork Producers, Smallholder/Backyard Producers, Veterinary Research Institutes & Laboratories), By Technology Platform (Conventional/Cell-Culture Based Platforms, Vector-Based/Recombinant Platforms, mRNA/Nucleic Acid-Based Platforms), By Dose Format/packaging (Single-Dose Vials, Multi-Dose Vials, Pre-Filled Syringes), By Vaccination Program Type (Core/Routine Herd Vaccination, Outbreak/Emergency Response Vaccination, Custom/Autogenous Vaccination Programs), and Regional Forecast, 2026-2034
Full table of contents for the published report, chapter by chapter.
- 01By Vaccine TypeInactivated · Live Attenuated Vaccines · Recombinant/Subunit Vaccines
- 02By Target DiseasePorcine Reproductive and Respiratory Syndrome · Porcine Circovirus Type 2 · Classical Swine Fever
- 03By ValencyMonovalent Vaccines · Bivalent Vaccines · Multivalent/Combination Vaccines
- 04By Route of AdministrationIntramuscular Injection · Subcutaneous Injection · Intranasal Administration
- 05By Production Stage/animal ClassSows & Gilts · Boars · Suckling Piglets
- 06By Distribution ChannelVeterinary Hospitals & Clinics · Retail Pharmacies/Agrovet Stores · Direct/Institutional Sales to Integrators
- 07By End User/farm TypeCommercial/Industrial Farms · Integrated Pork Producers · Smallholder/Backyard Producers
- 08By Technology PlatformConventional/Cell-Culture Based Platforms · Vector-Based/Recombinant Platforms · mRNA/Nucleic Acid-Based Platforms
- 09By Dose Format/packagingSingle-Dose Vials · Multi-Dose Vials · Pre-Filled Syringes
- 10By Vaccination Program TypeCore/Routine Herd Vaccination · Outbreak/Emergency Response Vaccination · Custom/Autogenous Vaccination Programs
- 11By Region
Market Analysis & Outlook
Swine vaccines are biological products administered to pigs to prevent or control viral and bacterial diseases affecting reproduction, respiratory health and growth performance across commercial and smallholder herds. They are formulated as inactivated, live attenuated, recombinant or nucleic-acid based products and are delivered by injection, intranasal spray or oral dosing depending on the target pathogen and production stage. Buyers range from large integrated pork producers and commercial farm operators purchasing directly from manufacturers to independent veterinary clinics, agrovet retailers and smallholder producers sourcing through local distribution channels.
Between 2025 and 2034 the global swine vaccines market moves from USD 1.85 billion to USD 3.411 billion, compounding at 7% a year. Fifteen years are covered in all, taking in USD 1.3 billion in 2020, USD 1.72 billion in 2024, USD 1.985 billion in 2026 and USD 2.602 billion in 2030.
44.98% of 2025 revenue sits in Inactivated (Killed) Vaccines, worth USD 0.833 billion and rising to USD 1.296 billion at 37.99% by 2034, the largest vaccine type line in both years. Growth is fastest in DNA/Nucleic Acid Vaccines at 13.95% and slowest in Inactivated (Killed) Vaccines at 4.98%. Share moves toward Recombinant/Subunit Vaccines and DNA/Nucleic Acid Vaccines and away from Inactivated (Killed) Vaccines, Live Attenuated Vaccines and Toxoid Vaccines, though no line shrinks in revenue terms.
Cut by target disease, the largest line is Porcine Reproductive and Respiratory Syndrome (PRRS): 21.98% of 2025 revenue, worth USD 0.407 billion, and 19.99% at USD 0.682 billion by 2034. African Swine Fever (ASF) grows faster at 17.13% against 5.9%, moving from 4% of revenue to 9% by 2034. Both this axis and the vaccine type one divide the same revenue, which is why they are alternative views, not components.
Asia Pacific is the largest region at 38% of 2025 revenue, worth USD 0.703 billion and reaching USD 1.399 billion by 2034. North America follows at 24%, moving from USD 0.444 billion to USD 0.75 billion, and Middle East and Africa is the smallest at 6%. Share shifts toward Asia Pacific over the forecast period, so the regional split repays a close reading.
The 2025 total is triangulated from published sources and category proxies, with no independently sourced count behind it. Segment, regional and country splits are estimated on the same basis, which bounds the precision of the figures above. Coverage runs to five regions, five vaccine type lines and ten segmentation axes across a fifteen-year window.
Market Size, 2020–2034
USD BillionRevenue in USD Billion. Values up to 2025 are actuals; 2026–2034 are forecast.
Key Takeaways
- The global swine vaccines market moves from USD 1.3 billion in 2020 to USD 1.85 billion in 2025 and USD 3.411 billion by 2034, the forecast period compounding at 7% a year.
- Inactivated (Killed) Vaccines is the largest vaccine type line at USD 0.833 billion in 2025, a 44.98% share, reaching USD 1.296 billion and 37.99% of revenue by 2034.
- At 13.95%, DNA/Nucleic Acid Vaccines grows faster than any other vaccine type line, moving from USD 0.093 billion and 5.02% of revenue in 2025 to USD 0.307 billion and 9% in 2034.
- Against a base case of USD 3.411 billion in 2034, the study also reports a bear case at USD 3.046 billion and a bull case at USD 3.813 billion, with the assumptions behind each set out separately.
- 38% of 2025 revenue is generated in Asia Pacific, worth USD 0.703 billion and rising to USD 1.399 billion by 2034; Middle East and Africa is smallest at 6%.
- 55% of Asia Pacific's base-year revenue comes from China alone: USD 0.387 billion in 2025, rising to USD 0.741 billion by 2034, which is why it is that region's worked example.
- The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and ten segmentation axes separately, with revenue, share and a growth rate for every line in each year.
Market Trends
Revenue Share, By vaccine type
Base year 2025Inactivated (Killed) Vaccines leads with 45.0% of vaccine type segment revenue.
Share of vaccine type segment revenue, most recent base year.
Read across the forecast period, the global swine vaccines market shows movement in three places: vaccine type composition, regional weight, and the 7% rate applied to the whole.
Not one of them points downward. Growth is everywhere in absolute terms, and the interest is entirely in where it lands.
Composition shifts on the vaccine type axis. DNA/Nucleic Acid Vaccines grows at 13.95% across 2026-2034 against 4.98% for Inactivated (Killed) Vaccines, the widest spread on the vaccine type axis. DNA/Nucleic Acid Vaccines takes its share of revenue from 5.02% to 9% while Inactivated (Killed) Vaccines gives up ground, from 44.98% to 37.99%. The revenue figures behind that are USD 0.093 billion to USD 0.307 billion and USD 0.833 billion to USD 1.296 billion. Both expand; where a supplier sits on the axis still decides whether it tracks the market.
Growth concentrates in Asia Pacific. Asia Pacific moves from 38% of revenue in 2025 to 41% in 2034, worth USD 0.703 billion rising to USD 1.399 billion. The remaining regions grow in absolute terms while giving up share: North America at 24% moving to 22%, Europe at 22% moving to 21%, Latin America at 10% moving to 10%, Middle East and Africa at 6% moving to 6%. That makes the regional split worth reading directly instead of scaling from the global rate: the same market rate produces different outcomes depending on where a supplier's revenue sits.
The series never breaks trajectory. Year by year the total runs USD 1.3 billion in 2020, USD 1.72 billion in 2024, USD 1.85 billion in 2025, USD 1.985 billion in 2026, USD 2.602 billion in 2030 and USD 3.411 billion in 2034. There is no discontinuity to time, and 7% forecast growth against 7.31% historical means the trend continues and does not turn. That moves the planning question away from timing a turn and onto the vaccine type and regional mixes, where the actual movement is.
Market Growth Factors
The fastest line decides the blended rate
Market Drivers
3- 01The fastest line decides the blended rate
DNA/Nucleic Acid Vaccines compounds at 13.95% against 7% for the market, rising from USD 0.093 billion in 2025 to USD 0.307 billion in 2034 and from 5.02% of revenue to 9%. Set against 4.98% at the other end of the axis, this is the line that decides whether the market's 7% holds. Exposure to this line, not to the market as a whole, is what determines a supplier's own rate.
- 02Asia Pacific carries 38% of the base and keeps growing
The largest regional base is Asia Pacific: USD 0.703 billion in 2025 at 38% of the global total, USD 1.399 billion by 2034 and 41%. North America is next at 24% of revenue, USD 0.444 billion in 2025 and USD 0.75 billion in 2034. Between them they hold most of the base and most of the revenue added over the period, so equal-weighting the regions in a plan misstates where the growth is.
- 03The base has grown every year since 2020
The historical period compounded at 7.31%; USD 1.3 billion in 2020, USD 1.72 billion in 2024 and USD 1.85 billion in 2025. The forecast continues at 7% to USD 3.411 billion in 2034. A forecast extending an observed trend is a different proposition from one proposing a turn, and that is why no ramp is applied: the 7% runs evenly across the period.
Growth drivers
| # | Growth driver | Impact | Gross contribution (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Commercialization of African Swine Fever vaccines and expanded biosecurity-driven vaccination mandates | High | +0.54 | Medium | High | High |
| 2 | Post-outbreak herd rebuilding and rising per-capita pork demand across Asia Pacific | High | +0.42 | High | Medium | Medium |
| 3 | Shift toward multivalent and combination vaccine formats that reduce handling events | Medium-High | +0.28 | Medium | Medium | High |
| 4 | Growth of recombinant and DNA-based vaccine platforms improving differentiation and safety | Medium-High | +0.25 | Low | Medium | High |
| 5 | Expansion of integrated and commercial farm vaccination protocols in Latin America and Southeast Asia | Medium | +0.2 | Medium | Medium | Medium |
| 6 | Others | Low | +0.1 | Low | Low | Low |
| Total | +1.79 | |||||
Restraints
| # | Restraint | Impact | Estimated reduction (USD Billion) | 2026-28 | 2029-31 | 2032-34 |
|---|---|---|---|---|---|---|
| 1 | Price sensitivity and lower vaccination penetration among smallholder and backyard producers | Medium-High | −0.12 | Medium | Medium | Medium |
| 2 | Cold-chain and logistics constraints limiting live-vaccine reach in remote production regions | Medium | −0.07 | Medium | Low | Low |
| 3 | Regulatory approval delays for new antigen platforms in key markets | Low | −0.06 | Medium | Low | Low |
| Total | −0.25 | |||||
Drivers contribute 1.79 USD Billion and restraints remove 0.25 USD Billion, a net 1.54 USD Billion, which is the revenue the market adds between the base year and 2034. Contributions are CDI estimates, apportioned so that they reconcile with the forecast rather than being read from it.
Separate the 7% into its parts and three show up: an already-large base compounding, the vaccine type mix moving toward its faster lines, and regional growth landing unevenly.
Restraining Factors
Downside case: USD 3.046 billion by 2034, against USD 3.411 billion in the base case
Market Restraints
2- 01Downside case: USD 3.046 billion by 2034, against USD 3.411 billion in the base case
Bear case assumes slower antigen approval timelines and continued herd consolidation delays that keep smallholder and backyard vaccination penetration close to current levels through 2034. On that assumption 2034 revenue lands at USD 3.046 billion against the USD 3.411 billion base case, from the same USD 1.85 billion 2025 starting point.
- 02Inactivated (Killed) Vaccines grows below the market rate
Inactivated (Killed) Vaccines carries 44.98% of 2025 revenue at USD 0.833 billion but compounds at 4.98% against 7% for the market, taking its share to 37.99% by 2034 even as revenue rises to USD 1.296 billion. Because it carries that much of the base, its pace holds the blended rate down more than any faster line lifts it.
Market Opportunities
What the bull case turns on
Market Opportunities
2- 01What the bull case turns on
A bull case of USD 3.813 billion by 2034, against USD 3.411 billion in the base case, turns on a single stated assumption: bull case assumes faster regulatory clearance and publicly supported rollout of African Swine Fever vaccines across additional Asia Pacific markets, sustaining higher vaccination coverage growth through the forecast period. The USD 1.85 billion 2025 base is common to both.
- 02DNA/Nucleic Acid Vaccines share moves from 5.02% to 9%
DNA/Nucleic Acid Vaccines grows at 13.95% against 7% for the market, adding revenue from USD 0.093 billion in 2025 to USD 0.307 billion in 2034 and taking its share from 5.02% to 9%. It is the place on this axis where share changes hands at scale, so it is where an entrant can take position without displacing the incumbent in Inactivated (Killed) Vaccines.
Market Challenges
Revenue is concentrated in Inactivated (Killed) Vaccines
Market Challenges
2- 01Revenue is concentrated in Inactivated (Killed) Vaccines
Inactivated (Killed) Vaccines is 44.98% of 2025 revenue at USD 0.833 billion and still 37.99% at USD 1.296 billion in 2034. No other single change on the vaccine type axis moves the total as much as a change in demand for that one line.
- 02Asia Pacific is largely China
China generates USD 0.387 billion of Asia Pacific's USD 0.703 billion in 2025, 55% of the region, reaching USD 0.741 billion by 2034. A regional number that depends this heavily on one country carries that country's specific conditions inside it, which a reader treating the region as diversified would miss.
Segmentation Analysis
10 axesThe market is divided by vaccine type and by target disease, valency, route of administration, production stage/animal class, distribution channel, end user/farm type, technology platform, dose format/packaging and vaccination program type; ten axes in all. Every one of them divides the same revenue, which makes them views of one market from different commercial angles, not components of it.
Five vaccine type lines are reported. Two of them take share over the forecast period and the rest give it up, though every line grows in absolute terms between 2025 and 2034.
By Vaccine Type · 5 segments
Scale in Inactivated (Killed) Vaccines and Growth in DNA/Nucleic Acid Vaccines Define the Vaccine type Axis
- Largest Inactivated (Killed) Vaccines · 45%
- Fastest DNA/Nucleic Acid Vaccines · 13.9%
- Moves most Inactivated (Killed) Vaccines · -7 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Inactivated (Killed) Vaccines | $0.83B | 45% | $1.30B | 38%-7 | 5% |
| Live Attenuated Vaccines | $0.56B | 30% | $0.89B | 26%-4 | 5.3% |
| Recombinant/Subunit Vaccines | $0.28B | 15% | $0.75B | 22%+7 | 11.5% |
| DNA/Nucleic Acid Vaccines | $0.09B | 5% | $0.31B | 9%+4 | 13.9% |
| Toxoid Vaccines | $0.09B | 5% | $0.17B | 5% | 7.1% |
Inactivated vaccines lead because their safety and regulatory familiarity make them the default choice across most licensed swine disease programs, particularly where cold-chain handling is already established. Recombinant and DNA-based platforms grow fastest as newer antigen designs allow producers to differentiate infected from vaccinated animals and address diseases such as African Swine Fever where live attenuated options carry safety concerns that regulators continue to weigh carefully. By 2034 Inactivated (Killed) Vaccines is still ahead, making this a shift in weight, not a change of leader. Every year of the series is priced on this axis, making it the reference cut for the rest of the report.
By Target Disease · 10 segments
By Target Disease
- Largest Porcine Reproductive and Respiratory Syndrome (PRRS) · 22%
- Fastest African Swine Fever (ASF) · 17.1%
- Moves most African Swine Fever (ASF) · +5 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Porcine Reproductive and Respiratory Syndrome (PRRS) | $0.41B | 22% | $0.68B | 20%-2 | 5.9% |
| Porcine Circovirus Type 2 (PCV2) | $0.30B | 16% | $0.51B | 15%-1 | 6.3% |
| Classical Swine Fever (CSF) | $0.17B | 9% | $0.27B | 8%-1 | 5.6% |
| African Swine Fever (ASF) | $0.07B | 4% | $0.31B | 9%+5 | 17.1% |
| Swine Influenza | $0.15B | 8% | $0.27B | 8% | 7% |
| Mycoplasma Hyopneumoniae (M. Hyo) | $0.24B | 13% | $0.41B | 12%-1 | 6% |
| Actinobacillus Pleuropneumoniae (APP) | $0.13B | 7% | $0.24B | 7% | 7% |
| Porcine Epidemic Diarrhea Virus (PEDV) & Enteric Diseases | $0.18B | 10% | $0.34B | 10% | 7% |
| Pseudorabies (Aujeszky's Disease) | $0.11B | 6% | $0.20B | 6% | 7.1% |
| Porcine Parvovirus & Erysipelas | $0.09B | 5% | $0.17B | 5% | 7% |
2025 to 2034 revenue and share by line: Porcine Reproductive and Respiratory Syndrome (PRRS) USD 0.407 billion to USD 0.682 billion (21.98% in 2025), Porcine Circovirus Type 2 (PCV2) USD 0.296 billion to USD 0.512 billion (15.98% in 2025), Mycoplasma Hyopneumoniae (M. Hyo) USD 0.241 billion to USD 0.409 billion (13.01% in 2025), Porcine Epidemic Diarrhea Virus (PEDV) & Enteric Diseases USD 0.185 billion to USD 0.341 billion (9.99% in 2025), Classical Swine Fever (CSF) USD 0.167 billion to USD 0.273 billion (9.02% in 2025), Swine Influenza USD 0.148 billion to USD 0.273 billion (7.99% in 2025), Actinobacillus Pleuropneumoniae (APP) USD 0.13 billion to USD 0.239 billion (7.02% in 2025), Pseudorabies (Aujeszky's Disease) USD 0.111 billion to USD 0.205 billion (5.99% in 2025), Porcine Parvovirus & Erysipelas USD 0.093 billion to USD 0.171 billion (5.02% in 2025), African Swine Fever (ASF) USD 0.074 billion to USD 0.307 billion (4% in 2025). African Swine Fever (ASF) Outpaces the Axis While Porcine Reproductive and Respiratory Syndrome (PRRS) Holds the Largest Share Porcine Reproductive and Respiratory Syndrome leads because it remains the costliest endemic disease in swine production, requiring routine revaccination across breeding and grow-finish herds in nearly every producing region. African Swine Fever grows fastest as newly commercialized vaccines give producers and authorities an active prevention option in markets that previously relied entirely on biosecurity measures and herd culling. The order does not change: Porcine Reproductive and Respiratory Syndrome (PRRS) is still largest in 2034, and what moves is how much it holds.
By Valency · 3 segments
Monovalent Vaccines Led by Valency in 2025, with Multivalent/Combination Vaccines Growing Fastest
- Largest Monovalent Vaccines · 40%
- Fastest Multivalent/Combination Vaccines · 9.9%
- Moves most Multivalent/Combination Vaccines · +8 pts
- Order by 2034 changes
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Monovalent Vaccines | $0.74B | 40% | $1.13B | 33%-7 | 4.8% |
| Bivalent Vaccines | $0.56B | 30% | $0.99B | 29%-1 | 6.6% |
| Multivalent/Combination Vaccines | $0.56B | 30% | $1.30B | 38%+8 | 9.9% |
Monovalent vaccines lead today because many disease-specific programs still call for single-antigen products matched to a particular pathogen and production stage. Multivalent and combination formats grow fastest as integrators and commercial farms consolidate vaccination events to reduce handling stress, labor time and injection-site trauma across large herds, favoring products that protect against several diseases in one dose. Leadership changes hands: Multivalent/Combination Vaccines is the largest line by 2034, not Monovalent Vaccines.
By Route of Administration · 4 segments
Intramuscular Injection Led by Route of administration in 2025, with Intranasal Administration Growing Fastest
- Largest Intramuscular Injection · 55%
- Fastest Intranasal Administration · 11.3%
- Moves most Intramuscular Injection · -7 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Intramuscular Injection | $1.02B | 55% | $1.64B | 48%-7 | 5.4% |
| Subcutaneous Injection | $0.46B | 25% | $0.82B | 24%-1 | 6.5% |
| Intranasal Administration | $0.22B | 12% | $0.58B | 17%+5 | 11.3% |
| Oral Administration | $0.15B | 8% | $0.38B | 11%+3 | 10.9% |
Intramuscular injection leads because it remains the default route specified on most licensed swine vaccine labels and matches existing farm handling routines. Intranasal administration grows fastest as needle-free formats reduce carcass bruising, injection-site lesions and labor time, appealing to large-scale operations seeking faster, lower-risk administration during routine vaccination rounds. By 2034 Intramuscular Injection is still ahead, making this a shift in weight, not a change of leader.
By Production Stage/animal Class · 5 segments
Scale in Sows & Gilts and Growth in Suckling Piglets Define the Production stage/animal class Axis
- Largest Sows & Gilts · 32%
- Fastest Suckling Piglets · 9.1%
- Moves most Suckling Piglets · +3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Sows & Gilts | $0.59B | 32% | $1.02B | 30%-2 | 6.3% |
| Boars | $0.11B | 6% | $0.20B | 6% | 7.1% |
| Suckling Piglets | $0.30B | 16% | $0.65B | 19%+3 | 9.1% |
| Weaners | $0.44B | 24% | $0.82B | 24% | 7% |
| Growers & Finishers | $0.41B | 22% | $0.72B | 21%-1 | 6.5% |
Sows and gilts carry the largest share because reproductive-health vaccination against PRRS, parvovirus and erysipelas is applied routinely across the breeding herd on a fixed calendar. Suckling piglets grow fastest as earlier-life immunization protocols close the gap left by declining maternal antibody protection in high-throughput, multi-site farrowing systems common in integrated production. Sows & Gilts remains the largest line through 2034, so the axis changes in proportion, not in order.
By Distribution Channel · 4 segments
Scale in Direct/Institutional Sales to Integrators and Growth in e-Commerce/Online Platforms Define the Distribution channel Axis
- Largest Direct/Institutional Sales to Integrators · 45%
- Fastest e-Commerce/Online Platforms · 14.6%
- Moves most e-Commerce/Online Platforms · +6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Veterinary Hospitals & Clinics | $0.52B | 28% | $0.89B | 26%-2 | 6.2% |
| Retail Pharmacies/Agrovet Stores | $0.37B | 20% | $0.65B | 19%-1 | 6.4% |
| Direct/Institutional Sales to Integrators | $0.83B | 45% | $1.43B | 42%-3 | 6.2% |
| e-Commerce/Online Platforms | $0.13B | 7% | $0.44B | 13%+6 | 14.6% |
Direct and institutional sales to integrators lead because large commercial operations negotiate supply contracts and cold-chain logistics directly with manufacturers, bypassing intermediaries. E-commerce platforms grow fastest as licensed online ordering and delivery extend to smaller and mid-sized producers who previously needed a clinic or agrovet store visit to access the same products. By 2034 Direct/Institutional Sales to Integrators is still ahead, making this a shift in weight, not a change of leader.
By End User/farm Type · 4 segments
Integrated Pork Producers Led by End user/farm type in 2025, with Veterinary Research Institutes & Laboratories Growing Fastest
- Largest Integrated Pork Producers · 38%
- Fastest Veterinary Research Institutes & Laboratories · 9.7%
- Moves most Smallholder/Backyard Producers · -3 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Commercial/Industrial Farms | $0.63B | 34% | $1.13B | 33%-1 | 6.7% |
| Integrated Pork Producers | $0.70B | 38% | $1.36B | 40%+2 | 7.6% |
| Smallholder/Backyard Producers | $0.37B | 20% | $0.58B | 17%-3 | 5.1% |
| Veterinary Research Institutes & Laboratories | $0.15B | 8% | $0.34B | 10%+2 | 9.7% |
Integrated pork producers lead because vertically coordinated operations standardize vaccination protocols across owned and contracted farms at scale, concentrating purchasing power. Veterinary research institutes and laboratories grow fastest off a small base as expanded trial, surveillance and regulatory work around African Swine Fever and other reportable diseases pulls in additional demand. The order does not change: Integrated Pork Producers is still largest in 2034, and what moves is how much it holds.
By Technology Platform · 3 segments
Scale in Conventional/Cell-Culture Based Platforms and Growth in mRNA/Nucleic Acid-Based Platforms Define the Technology platform Axis
- Largest Conventional/Cell-Culture Based Platforms · 65%
- Fastest mRNA/Nucleic Acid-Based Platforms · 15.6%
- Moves most Conventional/Cell-Culture Based Platforms · -13 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Conventional/Cell-Culture Based Platforms | $1.20B | 65% | $1.77B | 52%-13 | 4.4% |
| Vector-Based/Recombinant Platforms | $0.50B | 27% | $1.09B | 32%+5 | 9.1% |
| mRNA/Nucleic Acid-Based Platforms | $0.15B | 8% | $0.55B | 16%+8 | 15.6% |
Conventional and cell-culture based platforms lead because most currently licensed vaccine labels still rely on established inactivated and attenuated production lines with long regulatory track records. Nucleic-acid based platforms grow fastest as newly approved recombinant and DNA-based products for African Swine Fever and PRRS variants gain clearance across additional markets each year. The order does not change: Conventional/Cell-Culture Based Platforms is still largest in 2034, and what moves is how much it holds.
By Dose Format/packaging · 3 segments
Pre-Filled Syringes Outpaces the Axis While Multi-Dose Vials Holds the Largest Share
- Largest Multi-Dose Vials · 58%
- Fastest Pre-Filled Syringes · 12%
- Moves most Pre-Filled Syringes · +6 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Single-Dose Vials | $0.56B | 30% | $0.95B | 28%-2 | 6.2% |
| Multi-Dose Vials | $1.07B | 58% | $1.84B | 54%-4 | 6.2% |
| Pre-Filled Syringes | $0.22B | 12% | $0.61B | 18%+6 | 12% |
Multi-dose vials lead because large commercial and integrated operations vaccinate in high volumes where per-dose cost efficiency matters most to their procurement decisions. Pre-filled syringes grow fastest as smaller operations and contract vaccination crews value reduced handling, lower contamination risk and faster administration per animal during time-constrained vaccination rounds. Multi-Dose Vials remains the largest line through 2034, so the axis changes in proportion, not in order.
By Vaccination Program Type · 3 segments
Core/Routine Herd Vaccination Held the Dominant Share of the Vaccination program type Segment in 2025
- Largest Core/Routine Herd Vaccination · 72%
- Fastest Outbreak/Emergency Response Vaccination · 10.2%
- Moves most Core/Routine Herd Vaccination · -4 pts
- Order by 2034 unchanged
| Segment | 2025 | Share | 2034 | Share | CAGR |
|---|---|---|---|---|---|
| Core/Routine Herd Vaccination | $1.33B | 72% | $2.32B | 68%-4 | 6.4% |
| Outbreak/Emergency Response Vaccination | $0.18B | 10% | $0.44B | 13%+3 | 10.2% |
| Custom/Autogenous Vaccination Programs | $0.33B | 18% | $0.65B | 19%+1 | 7.7% |
Core and routine herd vaccination leads because most disease protection in swine still runs on scheduled, calendar-based programs rather than reactive treatment after exposure. Outbreak and emergency response vaccination grows fastest as newly licensed products give producers and authorities an active option for reportable diseases that previously had none available at all. Core/Routine Herd Vaccination remains the largest line through 2034, so the axis changes in proportion, not in order.
Regional Insights
Regional Revenue Share
Base year 2025Share of global revenue in the base year.
Only the leading region's share is published outside the report; pins mark the region, not a specific country.
North America Market Analysis
The 2nd-largest region covered — 2 points of share move elsewhere by 2034, while revenue still grows 1.7×.
- Rank 2 of 5
- 2025 share 24%
- By 2034 22%
- Revenue $0.44M → $0.75M
USD 0.444 billion of 2025 revenue is generated in North America, 24% of the global swine vaccines market with USD 0.75 billion projected for 2034. By revenue it sits second across the study, and the ranking does not change between 2025 and 2034.
Share settles at 22% in 2034, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
Within the region the vaccine type split tracks the global one; 44.98% of 2025 revenue in Inactivated (Killed) Vaccines, fastest growth of 13.95% in DNA/Nucleic Acid Vaccines. The full report breaks North America out along every axis and by country.
United States
Sets the pace for North America at 84.9% of it, growing 1.7×.
- In region 1 of 2
- Of region 84.9%
- Of global 20.4%
- Revenue $0.38M → $0.64M
The largest single market in North America is the United States, at USD 0.377 billion in 2025 and USD 0.638 billion in 2034. Because it is 84.9% of the region in the base year, North America's totals move with this one country instead of a spread of them. The region itself runs USD 0.444 billion to USD 0.75 billion over the same period, and this is the market carrying the country-level detail in the full report.
Composition here matches the global split: the largest line is Inactivated (Killed) Vaccines at 44.98% of 2025 revenue, easing to 37.99% by 2034, and the fastest is DNA/Nucleic Acid Vaccines at 13.95%, from 5.02% to 9%. Its 84.9% weight in North America means those movements carry straight into the regional totals. Revenue by vaccine type for the United States is reported separately in the full report.
Swine vaccines fall under the Center for Veterinary Biologics within the Animal and Plant Health Inspection Service, which regulates veterinary biologics separately from the Food and Drug Administration's oversight of animal drugs. A manufacturer must hold an establishment licence and secure product licensing for each vaccine, with efficacy and purity data reviewed before release. Serials are subject to lot release testing, and labelling must state the indicated pathogen, the target species, dosage, and withdrawal guidance where applicable. Facilities are inspected for compliance with the Virus-Serum-Toxin Act, and any change to formulation, adjuvant, or production process requires a supplemental filing. Import of foreign-manufactured vaccines follows the same licensing route as domestic production, so a supplier entering this market must demonstrate consistency of potency across serials rather than a single successful trial.
Zoetis Inc., Boehringer Ingelheim International GmbH, Merck & Co., Inc. (Merck Animal Health), Ceva Santé Animale, Elanco Animal Health Incorporated, Virbac S.A., Phibro Animal Health Corporation, Laboratorios Hipra, S.A., IDT Biologika GmbH, Biogénesis Bagó S.A., Vetoquinol S.A., Indian Immunologicals Limited, Brilliant Bio Pharma Ltd., Bioveta, a.s., Dyntec s.r.o., China Animal Husbandry Industry Co., Ltd. (CAHIC), Jinyu Bio-Technology Co., Ltd., Tianjin Ringpu Bio-technology Co., Ltd., Pulike Biological Engineering, Inc., Harbin Weike Biotechnology Development Company, Qilu Animal Health Products Co., Ltd., Wuhan Keqian Biology Co., Ltd., Yebio Bioengineering Co., Ltd. of Qingdao, Tecon Biology Co., Ltd. and Hester Biosciences Limited are the suppliers covered in the United States. The commercially relevant division is 44.98% of 2025 revenue in Inactivated (Killed) Vaccines, where the volume is, against 13.95% growth in DNA/Nucleic Acid Vaccines, where share moves. The full report covers country-level positioning and shares company by company; this summary does not.
Canada
2nd-largest in North America, growing 1.7×.
- In region 2 of 2
- Of region 15.1%
- Of global 3.6%
- Revenue $0.07M → $0.11M
3.6% of global revenue is generated in Canada; USD 0.067 billion in 2025, reaching USD 0.112 billion in 2034, and 15.1% of North America.
Europe Market Analysis
The 3rd-largest region covered — 1 point of share move elsewhere by 2034, while revenue still grows 1.8×.
- Rank 3 of 5
- 2025 share 22%
- By 2034 21%
- Revenue $0.41M → $0.72M
In Europe, 22% of global revenue puts 2025 at USD 0.407 billion and reaches USD 0.716 billion by 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.
21% of global revenue sits here in 2034, below the 2025 level, a shift in share, not in direction: revenue climbs every year while the market's centre of gravity moves elsewhere.
The vaccine type mix reported at global level applies here, with Inactivated (Killed) Vaccines the largest line at 44.98% of 2025 revenue and DNA/Nucleic Acid Vaccines the fastest-growing at 13.95%. The full report breaks Europe out along every axis and by country.
Spain
The largest market in Europe, growing 1.8×.
- In region 1 of 3
- Of region 30%
- Of global 6.6%
- Revenue $0.12M → $0.21M
The largest single market in Europe is Spain, at USD 0.122 billion in 2025 and USD 0.215 billion in 2034. Its 30% of base-year regional revenue leads the region, though enough sits elsewhere that Europe is not a proxy for it. Against regional totals of USD 0.407 billion in 2025 and USD 0.716 billion in 2034, it is the country the full report breaks out in detail.
The vaccine type pattern in Spain is the global one: 44.98% of 2025 revenue in Inactivated (Killed) Vaccines, 37.99% by 2034, against 13.95% growth in DNA/Nucleic Acid Vaccines taking it from 5.02% to 9%. Because the country carries 30% of Europe, a movement in its own mix shows up in the regional totals instead of being averaged away by neighbouring markets. The full report reports Spain by vaccine type separately.
As a member state, Spain applies the European Union's veterinary medicines framework, administered domestically through the Agencia Española de Medicamentos y Productos Sanitarios in coordination with the European Medicines Agency for products seeking a centralised authorisation. A swine vaccine must obtain a marketing authorisation before sale, supported by quality, safety, and efficacy dossiers, and each batch is subject to official control testing before release onto the market. Labelling must be in Spanish, stating the target species, route of administration, and any withdrawal period for meat destined for the food chain. Manufacturing sites are held to good manufacturing practice standards, and pharmacovigilance reporting continues after authorisation. A supplier changing an adjuvant or strain composition must seek a variation to the existing authorisation before distributing the updated product.
The suppliers tracked in this study (Zoetis Inc., Boehringer Ingelheim International GmbH, Merck & Co., Inc. (Merck Animal Health), Ceva Santé Animale, Elanco Animal Health Incorporated, Virbac S.A., Phibro Animal Health Corporation, Laboratorios Hipra, S.A., IDT Biologika GmbH, Biogénesis Bagó S.A., Vetoquinol S.A., Indian Immunologicals Limited, Brilliant Bio Pharma Ltd., Bioveta, a.s., Dyntec s.r.o., China Animal Husbandry Industry Co., Ltd. (CAHIC), Jinyu Bio-Technology Co., Ltd., Tianjin Ringpu Bio-technology Co., Ltd., Pulike Biological Engineering, Inc., Harbin Weike Biotechnology Development Company, Qilu Animal Health Products Co., Ltd., Wuhan Keqian Biology Co., Ltd., Yebio Bioengineering Co., Ltd. of Qingdao, Tecon Biology Co., Ltd. and Hester Biosciences Limited) compete in Spain across the vaccine type lines above. Volume sits in Inactivated (Killed) Vaccines at 44.98% of 2025 revenue; movement sits in DNA/Nucleic Acid Vaccines at 13.95% growth. The commercial size of that position is USD 0.407 billion in 2025, moving to USD 0.716 billion by 2034 across the forecast period.
Germany
2nd-largest in Europe, growing 1.8×.
- In region 2 of 3
- Of region 25.1%
- Of global 5.5%
- Revenue $0.10M → $0.18M
5.5% of global revenue is generated in Germany; USD 0.102 billion in 2025, reaching USD 0.179 billion in 2034, and 25.1% of Europe.
France
3rd-largest in Europe, growing 1.8×.
- In region 3 of 3
- Of region 17.9%
- Of global 3.9%
- Revenue $0.07M → $0.13M
France is sized at USD 0.073 billion in 2025, rising to USD 0.129 billion by 2034; 3.9% of global revenue and 17.9% of Europe. It is reported separately from Spain across every segmentation axis in the full report.
Asia Pacific Market Analysis
The largest region covered, and the one gaining the most — it picks up 3 points of share by 2034, while revenue still grows 2.0×.
- Rank 1 of 5
- 2025 share 38%
- By 2034 41%
- Revenue $0.70M → $1.40M
Asia Pacific holds 38% of the global swine vaccines market in 2025, worth USD 0.703 billion and reaches USD 1.399 billion by 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.
Share climbs to 41% by 2034, on growth above the market's own 7%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.
The vaccine type mix reported at global level applies here, with Inactivated (Killed) Vaccines the largest line at 44.98% of 2025 revenue and DNA/Nucleic Acid Vaccines the fastest-growing at 13.95%. Revenue for Asia Pacific is broken out by every segmentation axis and by country in the full report.
China
The largest market in Asia Pacific, growing 1.9×.
- In region 1 of 3
- Of region 55%
- Of global 20.9%
- Revenue $0.39M → $0.74M
55% of Asia Pacific's base-year revenue comes from China; USD 0.387 billion, rising to USD 0.741 billion by 2034. 55% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 0.703 billion in 2025 and USD 1.399 billion in 2034, it is the country the full report breaks out in detail.
Demand in China follows the vaccine type mix reported at global level: Inactivated (Killed) Vaccines is the largest line at 44.98% of 2025 revenue, moving to 37.99% by 2034, while DNA/Nucleic Acid Vaccines grows fastest at 13.95% and takes its share from 5.02% to 9%. Its 55% weight in Asia Pacific means those movements carry straight into the regional totals. Revenue by vaccine type for China is reported separately in the full report.
Swine vaccines are regulated by the Ministry of Agriculture and Rural Affairs, which classifies veterinary biological products separately from veterinary drugs and requires a New Veterinary Product Certificate before a vaccine can be manufactured or sold. Production is confined to licensed veterinary biologics plants, and each batch must pass compliance testing by an authorised institute before release, with certain vaccines subject to mandatory state batch issuance. Labelling must identify the target pathogen, strain, and storage conditions in Chinese, and cold chain handling is monitored through distribution. Vaccines addressing diseases under national control programmes, including classical and African swine fever, face additional procurement and deployment oversight tied to government eradication campaigns. A supplier must also register any imported strain or production change with the ministry before continued sale.
Competition in China runs between the suppliers this study tracks: Zoetis Inc., Boehringer Ingelheim International GmbH, Merck & Co., Inc. (Merck Animal Health), Ceva Santé Animale, Elanco Animal Health Incorporated, Virbac S.A., Phibro Animal Health Corporation, Laboratorios Hipra, S.A., IDT Biologika GmbH, Biogénesis Bagó S.A., Vetoquinol S.A., Indian Immunologicals Limited, Brilliant Bio Pharma Ltd., Bioveta, a.s., Dyntec s.r.o., China Animal Husbandry Industry Co., Ltd. (CAHIC), Jinyu Bio-Technology Co., Ltd., Tianjin Ringpu Bio-technology Co., Ltd., Pulike Biological Engineering, Inc., Harbin Weike Biotechnology Development Company, Qilu Animal Health Products Co., Ltd., Wuhan Keqian Biology Co., Ltd., Yebio Bioengineering Co., Ltd. of Qingdao, Tecon Biology Co., Ltd. and Hester Biosciences Limited. Two different problems sit on the same axis: holding Inactivated (Killed) Vaccines at 44.98% of 2025 revenue, and taking DNA/Nucleic Acid Vaccines while it grows at 13.95%. A supplier weighted toward Asia Pacific is competing over a base of USD 0.703 billion in 2025, reaching USD 1.399 billion by 2034 on the trajectory this study models.
Vietnam
2nd-largest in Asia Pacific, growing 2.3×.
- In region 2 of 3
- Of region 11.9%
- Of global 4.5%
- Revenue $0.08M → $0.20M
Vietnam is sized at USD 0.084 billion in 2025, rising to USD 0.196 billion by 2034; 4.5% of global revenue and 11.9% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.
Philippines
3rd-largest in Asia Pacific, growing 2.3×.
- In region 3 of 3
- Of region 7%
- Of global 2.6%
- Revenue $0.05M → $0.11M
Within Asia Pacific, the Philippines accounts for 7% of regional revenue and 2.6% of the global total, worth USD 0.049 billion in 2025 and USD 0.112 billion by 2034.
Latin America Market Analysis
The 4th-largest region covered, holding its share flat through 2034, while revenue still grows 1.8×.
- Rank 4 of 5
- 2025 share 10%
- By 2034 10%
- Revenue $0.18M → $0.34M
10% of the global swine vaccines market sits in Latin America in 2025, worth USD 0.185 billion rising to USD 0.341 billion in 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.
Share settles at 10% in 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.
The vaccine type mix reported at global level applies here, with Inactivated (Killed) Vaccines the largest line at 44.98% of 2025 revenue and DNA/Nucleic Acid Vaccines the fastest-growing at 13.95%. Latin America is reported axis by axis and country by country in the full study.
Brazil
The largest market in Latin America, growing 1.8×.
- In region 1 of 2
- Of region 55.1%
- Of global 5.5%
- Revenue $0.10M → $0.19M
The largest single market in Latin America is Brazil, at USD 0.102 billion in 2025 and USD 0.188 billion in 2034. It accounts for 55.1% of regional revenue in the base year, the largest single share without dominating the region outright. Against regional totals of USD 0.185 billion in 2025 and USD 0.341 billion in 2034, it is the country the full report breaks out in detail.
The vaccine type pattern in Brazil is the global one: 44.98% of 2025 revenue in Inactivated (Killed) Vaccines, 37.99% by 2034, against 13.95% growth in DNA/Nucleic Acid Vaccines taking it from 5.02% to 9%. With 55.1% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. The full report reports Brazil by vaccine type separately.
The Ministry of Agriculture, Livestock and Food Supply governs veterinary biological products through its Department of Animal Health, requiring a product registration before any swine vaccine can be manufactured, imported, or marketed. Registration dossiers must demonstrate safety, potency, and stability, and each batch produced or imported is subject to official quality control release. Labelling must appear in Portuguese and specify the target disease, species, storage requirements, and any slaughter withdrawal interval. Manufacturing facilities, whether domestic or supplying from abroad, must hold certification confirming compliance with the ministry's good manufacturing practice requirements. Vaccines directed at diseases under national surveillance, such as classical swine fever, are additionally coordinated with state veterinary services as part of herd health and export certification programmes, so a supplier's registration must stay aligned with the current disease status recognised by trading partners.
Zoetis Inc., Boehringer Ingelheim International GmbH, Merck & Co., Inc. (Merck Animal Health), Ceva Santé Animale, Elanco Animal Health Incorporated, Virbac S.A., Phibro Animal Health Corporation, Laboratorios Hipra, S.A., IDT Biologika GmbH, Biogénesis Bagó S.A., Vetoquinol S.A., Indian Immunologicals Limited, Brilliant Bio Pharma Ltd., Bioveta, a.s., Dyntec s.r.o., China Animal Husbandry Industry Co., Ltd. (CAHIC), Jinyu Bio-Technology Co., Ltd., Tianjin Ringpu Bio-technology Co., Ltd., Pulike Biological Engineering, Inc., Harbin Weike Biotechnology Development Company, Qilu Animal Health Products Co., Ltd., Wuhan Keqian Biology Co., Ltd., Yebio Bioengineering Co., Ltd. of Qingdao, Tecon Biology Co., Ltd. and Hester Biosciences Limited are the suppliers covered in Brazil. Inactivated (Killed) Vaccines, at 44.98% of 2025 revenue, is where the volume sits, and DNA/Nucleic Acid Vaccines, growing at 13.95%, is where position changes hands over the forecast period. A supplier weighted toward Latin America is competing over a base of USD 0.185 billion in 2025 reaching USD 0.341 billion by 2034, 10% of global revenue at the start of that period.
Mexico
2nd-largest in Latin America, growing 1.8×.
- In region 2 of 2
- Of region 30.3%
- Of global 3%
- Revenue $0.06M → $0.10M
Mexico is sized at USD 0.056 billion in 2025, rising to USD 0.102 billion by 2034; 3% of global revenue and 30.3% of Latin America. It is reported separately from Brazil across every segmentation axis in the full report.
Middle East and Africa Market Analysis
The 5th-largest region covered, holding its share flat through 2034, while revenue still grows 1.8×.
- Rank 5 of 5
- 2025 share 6%
- By 2034 6%
- Revenue $0.11M → $0.20M
Middle East and Africa holds 6% of the global swine vaccines market in 2025, worth USD 0.111 billion on the way to USD 0.205 billion by 2034. By revenue it sits fifth across the study, and the ranking does not change between 2025 and 2034.
Its share moves to 6% by 2034, while nothing contracts here; other regions simply grow faster, which shows up as relative weight, not as falling revenue.
The vaccine type mix reported at global level applies here, with Inactivated (Killed) Vaccines the largest line at 44.98% of 2025 revenue and DNA/Nucleic Acid Vaccines the fastest-growing at 13.95%. Middle East and Africa is reported axis by axis and country by country in the full study.
South Africa
Sets the pace for Middle East and Africa at 64.9% of it, growing 1.8×.
- In region 1 of 2
- Of region 64.9%
- Of global 3.9%
- Revenue $0.07M → $0.13M
The largest single market in Middle East and Africa is South Africa, at USD 0.072 billion in 2025 and USD 0.133 billion in 2034. Because it is 64.9% of the region in the base year, Middle East and Africa's totals move with this one country instead of a spread of them. Set against USD 0.111 billion and USD 0.205 billion for the region, it is why this market, and not a smaller one, is the one reported in full.
Composition here matches the global split: the largest line is Inactivated (Killed) Vaccines at 44.98% of 2025 revenue, easing to 37.99% by 2034, and the fastest is DNA/Nucleic Acid Vaccines at 13.95%, from 5.02% to 9%. With 64.9% of Middle East and Africa concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by vaccine type for South Africa is reported separately in the full report.
The Department of Agriculture, Land Reform and Rural Development regulates veterinary biologics through its Act governing stock remedies, and a swine vaccine must be registered with the relevant registrar before it can be sold or administered. Registration requires efficacy, safety, and stability data specific to local conditions, and imported vaccines must be manufactured at facilities recognised as meeting equivalent good manufacturing practice standards. Labelling must state the target disease, storage conditions, and any withdrawal period, and distribution is restricted to registered stock remedies unless an exemption applies. Vaccines against controlled or notifiable swine diseases are additionally subject to veterinary services oversight, since outbreak status affects both domestic movement controls and the country's disease-free standing for trade purposes. A supplier must maintain registration current with any change to strain or formulation.
Zoetis Inc., Boehringer Ingelheim International GmbH, Merck & Co., Inc. (Merck Animal Health), Ceva Santé Animale, Elanco Animal Health Incorporated, Virbac S.A., Phibro Animal Health Corporation, Laboratorios Hipra, S.A., IDT Biologika GmbH, Biogénesis Bagó S.A., Vetoquinol S.A., Indian Immunologicals Limited, Brilliant Bio Pharma Ltd., Bioveta, a.s., Dyntec s.r.o., China Animal Husbandry Industry Co., Ltd. (CAHIC), Jinyu Bio-Technology Co., Ltd., Tianjin Ringpu Bio-technology Co., Ltd., Pulike Biological Engineering, Inc., Harbin Weike Biotechnology Development Company, Qilu Animal Health Products Co., Ltd., Wuhan Keqian Biology Co., Ltd., Yebio Bioengineering Co., Ltd. of Qingdao, Tecon Biology Co., Ltd. and Hester Biosciences Limited are the suppliers covered in South Africa. Inactivated (Killed) Vaccines, at 44.98% of 2025 revenue, is where the volume sits, and DNA/Nucleic Acid Vaccines, growing at 13.95%, is where position changes hands over the forecast period. A supplier weighted toward Middle East and Africa is competing over a base of USD 0.111 billion in 2025, reaching USD 0.205 billion by 2034 on the trajectory this study models.
Kenya
2nd-largest in Middle East and Africa, growing 1.8×.
- In region 2 of 2
- Of region 15.3%
- Of global 0.9%
- Revenue $0.02M → $0.03M
Within Middle East and Africa, Kenya accounts for 15.3% of regional revenue and 0.9% of the global total, worth USD 0.017 billion in 2025 and USD 0.031 billion by 2034.
Download a free sample to see the full data tables and segment-level detail behind this analysis.
Report Coverage
This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by vaccine type, target disease, valency, route of administration, production stage/animal class, distribution channel, end user/farm type, technology platform, dose format/packaging, vaccination program type, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.
Competitive Landscape
Scale in Inactivated (Killed) Vaccines and Growth in DNA/Nucleic Acid Vaccines Set the Terms of Competition
Suppliers in scope: Zoetis Inc., Boehringer Ingelheim International GmbH, Merck & Co., Inc. (Merck Animal Health), Ceva Santé Animale, Elanco Animal Health Incorporated, Virbac S.A., Phibro Animal Health Corporation, Laboratorios Hipra, S.A., IDT Biologika GmbH, Biogénesis Bagó S.A., Vetoquinol S.A., Indian Immunologicals Limited, Brilliant Bio Pharma Ltd., Bioveta, a.s., Dyntec s.r.o., China Animal Husbandry Industry Co., Ltd. (CAHIC), Jinyu Bio-Technology Co., Ltd., Tianjin Ringpu Bio-technology Co., Ltd., Pulike Biological Engineering, Inc., Harbin Weike Biotechnology Development Company, Qilu Animal Health Products Co., Ltd., Wuhan Keqian Biology Co., Ltd., Yebio Bioengineering Co., Ltd. of Qingdao, Tecon Biology Co., Ltd. and Hester Biosciences Limited.
Competition follows the vaccine type split, not the regional one. The largest block of revenue is Inactivated (Killed) Vaccines: USD 0.833 billion in 2025 at 44.98% of the total, 37.99% in 2034. Incumbency there is expensive to challenge. The line that changes hands is DNA/Nucleic Acid Vaccines at 13.95%, well ahead of Inactivated (Killed) Vaccines at 4.98%. Those are different problems, and a supplier strong in one is not thereby strong in the other; that is what sustains a field this size in a USD 1.85 billion market.
Competition in swine vaccines centers on regulatory and approval experience, since new antigen platforms for diseases such as African Swine Fever require clearance in each market before a supplier can sell into it. The largest players combine broad manufacturing scale with established distribution reach into integrators and commercial farm networks, letting them bundle core and combination products into standing supply contracts. Regional manufacturers, concentrated in China, India and parts of Latin America and Eastern Europe, compete instead on price and proximity to local disease strains, often producing autogenous or region-specific formulations that global suppliers do not carry. Supply reliability during outbreak periods is a further point of separation that smaller players find harder to match consistently.
Geographic reach is the other axis of competition. Asia Pacific alone accounts for 38% of 2025 revenue, so a supplier absent there is absent from the largest part of the market whatever its position elsewhere; North America adds a further 24%.
Company-level profiles, financials, shares and development histories are held in the full report and not in this summary.
List of Key Swine Vaccines Market Companies Profiled
25 companies profiled. Company profiles, including financials, product portfolios and recent developments, are part of the full report.
- Zoetis Inc.(United States)
- Boehringer Ingelheim International GmbH(Germany)
- Merck & Co., Inc. (Merck Animal Health)(United States)
- Ceva Santé Animale(France)
- Elanco Animal Health Incorporated(United States)
- Virbac S.A.(France)
- Phibro Animal Health Corporation(United States)
- Laboratorios Hipra, S.A.(Spain)
- IDT Biologika GmbH(Germany)
- Biogénesis Bagó S.A.(Argentina)
- Vetoquinol S.A.(France)
- Indian Immunologicals Limited(India)
- Brilliant Bio Pharma Ltd.(India)
- Bioveta, a.s.(Czech Republic)
- Dyntec s.r.o.(Czech Republic)
- China Animal Husbandry Industry Co., Ltd. (CAHIC)(China)
- Jinyu Bio-Technology Co., Ltd.(China)
- Tianjin Ringpu Bio-technology Co., Ltd.(China)
- Pulike Biological Engineering, Inc.(China)
- Harbin Weike Biotechnology Development Company(China)
- Qilu Animal Health Products Co., Ltd.(China)
- Wuhan Keqian Biology Co., Ltd.(China)
- Yebio Bioengineering Co., Ltd. of Qingdao(China)
- Tecon Biology Co., Ltd.(China)
- Hester Biosciences Limited(India)
Geographic Coverage
Every market below is broken out separately in the report.
North America
3Europe
8Asia Pacific
12Latin America
3Middle East and Africa
4Key Insights
Report Scope
Study parameters & segmentationThis study covers market size and forecasts over the 2020–2034 period, segmentation across 10 axes (Vaccine Type, Target Disease, Valency, Route of Administration, Production Stage/animal Class, Distribution Channel, End User/farm Type, Technology Platform, Dose Format/packaging, Vaccination Program Type), regional analysis for 5 regions and their constituent countries, a competitive landscape profiling 25 key companies, and the research methodology behind every estimate.
Segmentation
10 axes + regionFull chapter-and-section structure of the report. Segment, region, and company breakdowns are listed as scope. The underlying figures are in the sample and full report.
Table of Contents+−
Chapter 1.Executive Summary
Chapter 2.Premium Insights
Chapter 3.Market Definition
Chapter 4.Research Methodology
Chapter 5.Strategic Imperatives & Market Outlook
Chapter 6.Go-to-Market (GTM) Strategies
Chapter 7.Market Trends, Strategy & Dynamics
Chapter 8.Porter's Five Forces
Chapter 9.PESTEL Analysis
Chapter 10.Value Chain Analysis
Chapter 11.Supply Chain Analysis
Chapter 12.Macro-Economic Factors
Chapter 13.Market Cost Analysis
Chapter 14.Market Supply-Side Analysis
Chapter 15.Global Swine Vaccines Market Size & Projections, 2020–2034, Revenue (USD Billion)
Chapter 16.Global Swine Vaccines Market Overview, By Vaccine Type, 2020–2034, Revenue (USD Billion)
Chapter 17.Global Swine Vaccines Market Overview, By Target Disease, 2020–2034, Revenue (USD Billion)
Chapter 18.Global Swine Vaccines Market Overview, By Valency, 2020–2034, Revenue (USD Billion)
Chapter 19.Global Swine Vaccines Market Overview, By Route of Administration, 2020–2034, Revenue (USD Billion)
Chapter 20.Global Swine Vaccines Market Overview, By Production Stage/animal Class, 2020–2034, Revenue (USD Billion)
Chapter 21.Global Swine Vaccines Market Overview, By Distribution Channel, 2020–2034, Revenue (USD Billion)
Chapter 22.Global Swine Vaccines Market Overview, By End User/farm Type, 2020–2034, Revenue (USD Billion)
Chapter 23.Global Swine Vaccines Market Overview, By Technology Platform, 2020–2034, Revenue (USD Billion)
Chapter 24.Global Swine Vaccines Market Overview, By Dose Format/packaging, 2020–2034, Revenue (USD Billion)
Chapter 25.Global Swine Vaccines Market Overview, By Vaccination Program Type, 2020–2034, Revenue (USD Billion)
Chapter 26.Global Swine Vaccines Market Size — Segment Comparison
Chapter 27.Global Swine Vaccines Geography Overview, 2020–2034, Revenue (USD Billion)
Chapter 28.North America Swine Vaccines Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 29.Europe Swine Vaccines Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 30.Asia Pacific Swine Vaccines Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 31.Latin America Swine Vaccines Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 32.Middle East and Africa Swine Vaccines Market Deep-Dive, 2020–2034, Revenue (USD Billion)
Chapter 33.Application / Use-Case Analysis
Chapter 34.Vendor Capability Scorecard
Chapter 35.Scenario Forecasts
Chapter 36.Top 10 Key Clients of Top 10 Players
Chapter 37.Top 10 Suppliers
Chapter 38.Competitive Landscape
Chapter 39.Partnerships & M&A
Chapter 40.Key Vendor Analysis
Chapter 41.Marketing Strategy Analysis, Distributors & Traders
Chapter 42.Outlook of the Market
Chapter 43.Concluding Analyst Note
List of Figures+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual figure numbering.
List of Tables+−
Structural index generated from this report's own section headings, not verified against the delivered report's actual table numbering.
Segmentation Analysis
10 axesBy Vaccine Type
5- 01Inactivated (Killed) Vaccines
- 02Live Attenuated Vaccines
- 03Recombinant/Subunit Vaccines
- 04DNA/Nucleic Acid Vaccines
- 05Toxoid Vaccines
By Target Disease
10- 01Porcine Reproductive and Respiratory Syndrome (PRRS)
- 02Porcine Circovirus Type 2 (PCV2)
- 03Classical Swine Fever (CSF)
- 04African Swine Fever (ASF)
- 05Swine Influenza
- 06Mycoplasma Hyopneumoniae (M. Hyo)
- 07Actinobacillus Pleuropneumoniae (APP)
- 08Porcine Epidemic Diarrhea Virus (PEDV) & Enteric Diseases
- 09Pseudorabies (Aujeszky's Disease)
- 10Porcine Parvovirus & Erysipelas
By Valency
3- 01Monovalent Vaccines
- 02Bivalent Vaccines
- 03Multivalent/Combination Vaccines
By Route of Administration
4- 01Intramuscular Injection
- 02Subcutaneous Injection
- 03Intranasal Administration
- 04Oral Administration
By Production Stage/animal Class
5- 01Sows & Gilts
- 02Boars
- 03Suckling Piglets
- 04Weaners
- 05Growers & Finishers
By Distribution Channel
4- 01Veterinary Hospitals & Clinics
- 02Retail Pharmacies/Agrovet Stores
- 03Direct/Institutional Sales to Integrators
- 04e-Commerce/Online Platforms
By End User/farm Type
4- 01Commercial/Industrial Farms
- 02Integrated Pork Producers
- 03Smallholder/Backyard Producers
- 04Veterinary Research Institutes & Laboratories
By Technology Platform
3- 01Conventional/Cell-Culture Based Platforms
- 02Vector-Based/Recombinant Platforms
- 03mRNA/Nucleic Acid-Based Platforms
By Dose Format/packaging
3- 01Single-Dose Vials
- 02Multi-Dose Vials
- 03Pre-Filled Syringes
By Vaccination Program Type
3- 01Core/Routine Herd Vaccination
- 02Outbreak/Emergency Response Vaccination
- 03Custom/Autogenous Vaccination Programs
Segment categories shown for scope reference. See the Summary tab for revenue share by Vaccine Type. Full segment-by-segment detail across every axis is available in the sample and full report.
Research approach
A market size is a claim about the world, and a claim is only as good as the route to it. Every study is built upward from units and prices — what is actually produced, sold or performed, at what it actually changes hands for — rather than from a headline figure divided downwards. Disclosed company revenue is then used to check that build, not to produce it.
This market was built upward from vaccine dose volumes and realised prices rather than estimated from the top. Annual dose volumes were derived from national pig herd inventories, sow and gilt populations, and typical vaccination schedules for PRRS, PCV2, Mycoplasma hyopneumoniae and other core diseases, then multiplied by per-dose pricing observed across monovalent, multivalent and recombinant product lines. That bottom-up figure was checked against the disclosed animal health segment revenue of Zoetis, Boehringer Ingelheim, Merck Animal Health and Ceva Santé Animale, apportioned to swine using their reported species mix. Where the two diverged, the herd-size or dosing-frequency assumption feeding the bottom-up build was revisited and corrected, not averaged against the disclosed figure.
The four stages
The same sequence runs behind every published study, whatever the industry. The order matters as much as the steps: the segment axes are fixed before any number is collected, so the model is never reshaped to fit whatever data happens to turn up.
What the build rests on, and what checks it
The two are not interchangeable. The left column produces the number; the right column tests it. When the check disagrees with the build, the answer is to find which bottom-up assumption is wrong — a unit count, a price, a take-up rate — not to split the difference between them.
- Volume actually transacted — units produced, installed, dispensed or procedures performed, counted at the level each is genuinely recorded
- Realised pricing by tier and channel, rather than one blended average applied across the whole market
- Take-up and frequency: how much of the addressable base buys, and how often it repeats
- Disclosed revenue of the companies serving the market, where filings separate it far enough to be usable
- Buyer-side spending totals — capital budgets, procurement lines, or the output of the end market the product is bought against
- Trade and customs flows, where the product crosses borders in a separately recorded form
Data sources
Published data establishes what happened. Only the people transacting in a market can say why, and what is about to change — so the two are collected separately and weighted differently.
- Commercial and product leadership at the companies that supply the market
- Procurement and specification leads at the organisations that buy it
- Distributors, integrators and channel partners, where the market is served indirectly
- Regulatory and standards specialists, where approval governs what can be sold at all
- Company filings, annual reports and investor disclosure
- Government statistics, customs records and regulatory registers
- Trade association output and standards-body publications
- Technical and peer-reviewed literature, where the market rests on a clinical or engineering claim
Interviews were directed at procurement and technical leads inside integrated pork producers and commercial farm groups, who set vaccination protocols and negotiate direct supply contracts, alongside veterinary practitioners at mixed-animal and swine-focused clinics who influence product choice for smaller operations. Distribution and channel managers at agrovet retailers and institutional distributors were sampled to confirm how pricing and availability differ between direct sales and retail channels, and regulatory affairs contacts were included to track antigen approval timing for newer recombinant and nucleic-acid platforms. Sampling weighted toward China, the United States, Spain, Germany, Brazil and Vietnam, reflecting where herd populations and vaccine spending concentrate.
Desk research drew on national veterinary product registers and marketing authorisation databases in the United States, European Union and China to track which antigens and platforms hold current approval, together with customs trade data under the relevant animal-vaccine tariff codes to observe cross-border shipment volumes. National agriculture ministry herd census figures for major pork-producing countries anchored the population base used in dose-volume calculations, and company filings and investor disclosures from the largest animal health suppliers were reviewed for species-level revenue splits. Trade body benchmarks from pork producer associations in the United States, European Union and Brazil supplied vaccination-rate and herd-health-spending reference points.
Desk research runs across proprietary research databases including Factiva, OneSource and Hoovers alongside the public sources above. Modelling and statistical validation are run in SAS and SPSS.
Forecasting
The forecast is not a growth rate applied to a base year. It is built from the drivers that are expected to change, each one stated so a reader can disagree with it.
The forecast is built from expected herd population trends in major pork-producing countries, the pace at which newly approved recombinant and nucleic-acid vaccines gain label clearance in additional markets, and the continued shift of production toward integrated operations that vaccinate on standing protocols rather than as needed. Pricing is assumed roughly flat in real terms for established categories while newer platforms carry a premium that narrows as manufacturing scale increases. The African Swine Fever vaccine rollout is treated as a genuine step change in several Asian markets rather than smoothed into the trend line. For the forecast to hold, herd rebuilding after past disease outbreaks needs to continue at a broadly steady pace.
Triangulation and validation
No figure enters a report on the strength of one source. Where the two sizing routes disagree the difference is not averaged away — the assumption causing it is isolated, tested against a third independent measure, and either corrected or carried forward as a stated limitation. Historical years are back-tested against the growth actually recorded before any forecast is allowed to run forward from them.
Forecast segment growth rates were back-tested against recorded vaccination spending growth in the United States and European Union over the past five years to confirm they sit within a plausible range rather than extrapolating an unsustainable curve. Segment share shifts, particularly the move toward multivalent formats and nucleic-acid platforms, were reviewed against the same veterinary and distribution contacts interviewed during primary research to confirm the direction and rough pace matched what they observe in ordering patterns. Sensitivities were run on herd population growth, African Swine Fever vaccine approval timing, and per-dose pricing for newer platforms, since these three assumptions carry the largest effect on the 2034 total if any of them run ahead of or behind the base case.
Confidence and limitations
Where an estimate is firm and where it is not is stated rather than left to be inferred from the precision of the number.
Confidence is firmer for established categories, inactivated and live attenuated vaccines against PRRS, PCV2 and Mycoplasma hyopneumoniae, where dose volumes and pricing are anchored to disclosed company revenue and long-running national herd data. It is weaker for recombinant and nucleic-acid platforms and for African Swine Fever vaccination specifically, where adoption is recent, approval status still varies market by market, and reporting from smaller regional manufacturers is thin. A structural risk worth naming is that a slower-than-assumed pace of new antigen approvals in Asia Pacific would flatten the fastest-growing segments in this forecast without changing the outlook for the established categories at all.
Every report purchase includes direct access to the lead analyst for scoping questions on the data, at no extra cost and with no separate booking process.
Request a tailored breakdown by geography, segment, or competitor set beyond what's in the standard report.
Questions This Report Answers
6 questionsWhat is the market size and growth rate, globally and by region?
How is the market segmented, and which segments lead?
Which regions and countries are covered, and how do they compare?
What are the key drivers, restraints, opportunities and challenges?
Who are the leading companies operating in this market?
What trends are expected to shape the market through the forecast period?
Frequently Asked Questions
01What is the Swine Vaccines Market projected to reach?
USD 3.411 USD Billion by 2034, CAGR 7%
02What years does this report cover?
Study period 2020–2034, base year 2025, historical data 2020-2024, forecast period 2026-2034.
03Which regions are covered?
North America, Europe, Asia Pacific, Latin America, Middle East and Africa.
04Which region accounted for the largest market share?
Asia Pacific leads with 38% of global revenue through 2034.
05Which segment leads the market?
Inactivated (Killed) Vaccines is the largest line by vaccine type, at 44.98% of revenue in 2025.
06Who are the key companies profiled?
Zoetis Inc., Boehringer Ingelheim International GmbH, Merck & Co., Inc. (Merck Animal Health), Ceva Santé Animale, Elanco Animal Health Incorporated, Virbac S.A., Phibro Animal Health Corporation, Laboratorios Hipra, S.A., IDT Biologika GmbH, Biogénesis Bagó S.A., Vetoquinol S.A., Indian Immunologicals Limited, Brilliant Bio Pharma Ltd., Bioveta, a.s., Dyntec s.r.o., China Animal Husbandry Industry Co., Ltd. (CAHIC), Jinyu Bio-Technology Co., Ltd., Tianjin Ringpu Bio-technology Co., Ltd., Pulike Biological Engineering, Inc., Harbin Weike Biotechnology Development Company, Qilu Animal Health Products Co., Ltd., Wuhan Keqian Biology Co., Ltd., Yebio Bioengineering Co., Ltd. of Qingdao, Tecon Biology Co., Ltd., Hester Biosciences Limited. Full profiles are part of the paid report.
07Can the segmentation be customized?
Yes. Custom data cuts by geography, segment, or competitor set are available on request.
Why choose CDI
Need this report shaped around your question?
The scope isn't fixed. Tell us what your team needs that the standard edition doesn't cover, and an analyst will come back on what can be adjusted and how long it takes, before you commit to anything.
Most licences include 30–60 hours of customization at no extra cost. See what each licence includes
Additional Companies
Add competitors, suppliers or the peer set you benchmark against to the companies already covered.
Deeper Competitive View
Sharpen the landscape work around your own position: product line, channel, or a named shortlist of rivals.
Extra Segment Splits
Break the market down along an axis the standard scope doesn't cut it by, or go a level deeper inside one.
Application Focus
Narrow the analysis to the specific use cases and end users your team actually sells into.
Different Time Frame
Move the base year, or widen the historical and forecast windows the study is built on.
Country-Level Detail
Go below region level into the individual countries that matter to you, rather than the standard geography split.